Dental Practice Sale Earnouts and Equity Rollovers Explained (2026)
In a 2026 DSO dental deal, only 60-80% of the headline price is guaranteed cash at close. The rest is split between earnouts (performance-contingent payments over 12-36 months) and rollover equity (15-40% reinvested in the DSO’s parent company, illiquid for 5-7 years).
A $5M offer is not $5M. Understanding how these two components actually pay out, and how often they don’t, is the difference between a good deal and a disappointing one.
This guide explains earnouts and rollover equity in plain terms, the realization risk in each, and how to negotiate them.
For the full deal context, see our guides to DSO acquisition offers and associate vs. DSO. Pennsylvania sellers should also review our Pennsylvania dental practice sale guide for how PA Medicaid re-enrollment timing affects earnout negotiations.
Earnouts: Getting Paid for Performance You Don’t Fully Control
An earnout is a portion of your purchase price paid after closing, contingent on the practice hitting agreed performance targets (usually retained EBITDA or production) over a defined period.
Typical Earnout Structure in 2026
- Period: 12-36 months, with 24 months most common
- Size: often the gap between cash at close and total deal value, after rollover
- Metrics: retained EBITDA, collections, production targets, or associate retention
The Core Earnout Risk
Once you sell, you no longer fully control the practice. The DSO makes operational changes (fee schedules, staffing, scheduling systems, supply vendors) that can affect your ability to hit the targets.
If production declines, you may not receive the full earnout. Longer earnout periods (36 months) carry significantly more non-payment risk than shorter ones, because more can change beyond your control.
The Associate-Retention Trap
Dental earnouts are frequently tied to associate retention. If associates walk during or shortly after the transition, you can face earnout claw-back, a price reduction, or even deal collapse.
This makes locking in associate retention contracts before sale one of the highest-leverage preparation moves.
How to Negotiate a Better Earnout
- Linear payouts, not cliffs: pro-rata achievement (you get paid for partial performance) beats all-or-nothing thresholds
- Locked expense allocations: agree in writing how EBITDA will be calculated so the DSO can’t allocate corporate costs to depress your number
- Protection against buyer actions: carve out the impact of DSO-imposed changes that reduce achievability
- Acceleration on sale: negotiate that if the DSO sells your practice during the earnout, remaining payments accelerate (many deals lack this by default)
Rollover Equity: The Second Bite at the Apple
Rollover equity is the portion of your proceeds (typically 15-40%) that you reinvest as an ownership stake in the DSO’s parent company instead of taking as cash.
The pitch: when the DSO recapitalizes or sells to the next PE buyer in 3-7 years, your equity produces a second payout.
How Rollover Works
- Instead of 100% cash, you take some cash plus equity in the DSO’s parent entity
- The stake is typically small (often 1-5% of the parent, depending on your practice’s size relative to the platform)
- If the DSO sells at a higher multiple later, your stake can be worth 2-3x what you rolled
- If the DSO underperforms or doesn’t achieve a successful exit, the stake can be worth little or nothing
The Rollover Risks Most Sellers Miss
Illiquidity: rolled equity is locked for 5-7 years until the platform’s next liquidity event. You can’t monetize it on your timeline.
Forfeiture: termination for cause or breach can trigger mandatory buyout at a reduced valuation, or total forfeiture of the equity.
No control over exit: sellers often have little or no say in when the DSO sells. Many wrongly assume they control their own exit.
Dilution: without protection, later capital raises can dilute your stake.
It primarily benefits the DSO: rollover reduces the DSO’s cash outlay and aligns your incentives to their performance. The upside framing is real but it serves the buyer first.
How to Protect Your Rollover
- Tag-along rights: you can sell when they sell
- Put options: you can force them to buy your equity at predetermined terms
- Information rights: quarterly financials so you can monitor platform performance
- Anti-dilution protections: shield your stake from future capital raises
The Math: Why a $5M Offer Isn’t $5M
Take a $5M DSO offer with typical structure:
- Cash at close (70%): $3.5M guaranteed
- Rollover equity (20%): $1M invested, worth $0 to $3M+ depending on the DSO’s exit in 5-7 years
- Earnout (10%): $500K, paid only if you hit targets over 24 months
The guaranteed value is $3.5M. The other $1.5M is probabilistic. A disciplined seller risk-adjusts: maybe the earnout is 70% likely ($350K expected) and the rollover has a wide range.
The expected realized value might be $4.2M-$4.5M, not $5M, and the downside could be $3.5M if the earnout misses and the rollover underwhelms.
This is why comparing a DSO offer to an associate offer on headline numbers is a mistake. A mostly-guaranteed associate deal at a lower headline can beat a structured DSO deal once you risk-adjust.
See our associate vs. DSO comparison for the full framework.
| Deal Component | Typical Range | On a $5M Offer | Key Risk |
|---|---|---|---|
| Cash at close | 60–80% | $3M–$4M | Low — paid at close |
| Earnout | 10–20% | $500K–$1M | Tied to production targets you may not control |
| Rollover equity | 10–30% | $500K–$1.5M | Illiquid until platform exits (typically 5–8 years) |
| Rollover upside (2nd exit) | 2x–4x rollover value | $1M–$6M potential | Depends entirely on platform performance |
The LOI Is Where This Gets Decided
Earnout and rollover terms are set in the letter of intent, and most dentists sign the LOI focused only on the headline number. DSO development teams are trained negotiators who have done hundreds of deals and know which terms to make “standard.”
Even non-binding LOI terms create anchoring effects: once “agreed,” changing them later is treated as bad-faith renegotiation.
Get the earnout structure (linear vs. cliff), EBITDA calculation method, rollover protections (tag-along, put options), and acceleration terms negotiated before you sign the LOI, not after. By the time you’re in the purchase agreement, the leverage is gone.
For how the full timeline unfolds, see our dental practice sale timeline.
Earnouts and Rollover Equity FAQ
What percentage of a DSO deal is cash vs. earnout vs. rollover?
Typically 60-80% cash at close, 15-40% rollover equity, and the remainder in earnouts. Only the cash at close is guaranteed. The exact split varies by DSO and by how well the practice is positioned.
How long is a typical dental earnout period?
Most dental earnout periods run 12-36 months, with 24 months being most common. Longer periods carry more non-payment risk because more operational change can occur beyond the seller’s control.
What happens to my earnout if the DSO changes how the practice runs?
DSO-imposed changes (fee schedules, staffing, vendors, scheduling systems) can reduce production and threaten your earnout targets. This is why you should negotiate locked expense allocations and carve-outs for buyer-driven changes that affect achievability before signing the LOI.
Is rollover equity guaranteed to pay out?
No. Rollover equity pays out only if the DSO achieves a successful recapitalization or sale, typically in 5-7 years. It can be worth 2-3x what you rolled if the platform performs, or little to nothing if it doesn’t. It’s also illiquid and can be subject to forfeiture.
Can I lose my rollover equity?
Yes. Rollover equity can be forfeited if you’re terminated for cause or breach your agreement, sometimes triggering a mandatory buyout at a reduced valuation or total forfeiture. Negotiate put options and clear forfeiture terms to limit this risk.
What protections should I negotiate on rollover equity?
Tag-along rights (sell when they sell), put options (force them to buy your stake at set terms), information rights (quarterly financials), and anti-dilution protections. These keep a small, illiquid stake from becoming a trapped one.
Why does the LOI matter so much for earnouts and rollover?
The LOI sets the earnout structure, EBITDA calculation method, and rollover terms. Even non-binding LOI terms anchor the deal, and changing them later is treated as bad-faith renegotiation. Negotiate these terms before signing the LOI, while you still have leverage.